Hong Kong · Delayed Price · Currency is HKD Gaush Meditech Statistics
Total Valuation
Gaush Meditech has a market cap or net worth of HKD 1.29 billion. The enterprise value is 1.40 billion.
| Market Cap | 1.29B |
| Enterprise Value | 1.40B |
Important Dates
The next estimated earnings date is Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | Jun 23, 2025 |
Share Statistics
Gaush Meditech has 145.33 million shares outstanding. The number of shares has decreased by -0.77% in one year.
| Current Share Class | 145.33M |
| Shares Outstanding | 145.33M |
| Shares Change (YoY) | -0.77% |
| Shares Change (QoQ) | -1.13% |
| Owned by Insiders (%) | 44.51% |
| Owned by Institutions (%) | 0.98% |
| Float | 50.06M |
Valuation Ratios
The trailing PE ratio is 11.70.
| PE Ratio | 11.70 |
| Forward PE | n/a |
| PS Ratio | 0.82 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 3.37 |
| P/FCF Ratio | 9.43 |
| P/OCF Ratio | 8.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.15, with an EV/FCF ratio of 10.21.
| EV / Earnings | 12.54 |
| EV / Sales | 0.89 |
| EV / EBITDA | 5.15 |
| EV / EBIT | 7.78 |
| EV / FCF | 10.21 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.40 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 3.75 |
| Interest Coverage | 6.16 |
Financial Efficiency
Return on equity (ROE) is 6.03% and return on invested capital (ROIC) is 4.75%.
| Return on Equity (ROE) | 6.03% |
| Return on Assets (ROA) | 3.81% |
| Return on Invested Capital (ROIC) | 4.75% |
| Return on Capital Employed (ROCE) | 7.68% |
| Revenue Per Employee | 1.93M |
| Profits Per Employee | 136,329 |
| Employee Count | 884 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.11 |
Taxes
In the past 12 months, Gaush Meditech has paid 73.15 million in taxes.
| Income Tax | 73.15M |
| Effective Tax Rate | 40.65% |
Stock Price Statistics
The stock price has decreased by -18.65% in the last 52 weeks. The beta is -0.07, so Gaush Meditech's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -18.65% |
| 50-Day Moving Average | 9.12 |
| 200-Day Moving Average | 7.49 |
| Relative Strength Index (RSI) | 44.42 |
| Average Volume (20 Days) | 51,120 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gaush Meditech had revenue of HKD 1.58 billion and earned 111.65 million in profits. Earnings per share was 0.76.
| Revenue | 1.58B |
| Gross Profit | 735.57M |
| Operating Income | 179.94M |
| Pretax Income | 179.98M |
| Net Income | 111.65M |
| EBITDA | 246.63M |
| EBIT | 179.94M |
| Earnings Per Share (EPS) | 0.76 |
Balance Sheet
The company has 420.42 million in cash and 513.98 million in debt, giving a net cash position of -93.56 million or -0.64 per share.
| Cash & Cash Equivalents | 420.42M |
| Total Debt | 513.98M |
| Net Cash | -93.56M |
| Net Cash Per Share | -0.64 |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 12.54 |
| Working Capital | 667.38M |
Cash Flow
In the last 12 months, operating cash flow was 156.21 million and capital expenditures -19.06 million, giving a free cash flow of 137.14 million.
| Operating Cash Flow | 156.21M |
| Capital Expenditures | -19.06M |
| Free Cash Flow | 137.14M |
| FCF Per Share | 0.94 |
Margins
Gross margin is 46.63%, with operating and profit margins of 11.41% and 7.08%.
| Gross Margin | 46.63% |
| Operating Margin | 11.41% |
| Pretax Margin | 11.41% |
| Profit Margin | 7.08% |
| EBITDA Margin | 15.64% |
| EBIT Margin | 11.41% |
| FCF Margin | 8.69% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 3.37%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 3.37% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 145.79% |
| Buyback Yield | 0.77% |
| Shareholder Yield | 4.07% |
| Earnings Yield | 8.63% |
| FCF Yield | 10.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gaush Meditech has an Altman Z-Score of 2.74 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.74 |
| Piotroski F-Score | 8 |